Centre for Amyloidosis
Information for patients on the coronavirus (COVID-19)
UPDATE: As of 01 June 2020 the National Amyloidosis Centre has reopened. We will be conducting clinics via telephone/video-link, or where appropriate, in person. We will be in touch to let you know what type of appointment you will be having.
For FEVER PATIENTS who receive treatments at the Centre, such as Canakinumab, Anakinra and Tocilizumab, they will continue to have their appointments at this time. Please contact Michael Wood or Bella Sombrito if you have any questions.
These teams undertake world leading, wide ranging, basic and clinical research on amyloid and amyloidosis, C‑reactive protein and serum amyloid A protein, leading to design and development of new treatments.
Head of Centre
Director of the Wolfson Drug Discovery Unit